This article on MSBT looks like a regurgitation of the CEOspeak from 6 months ago. Nothing new here for now. Look for results from German trial in a month or two. I sold my positions this morning for nice profits. Will buy back in the teens.
A.P. Pharma, Inc. (NASDAQ: APPA) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company's primary focus is on its lead product candidate, APF530, which has completed a pivotal Phase 3 clinical trial for the prevention of CINV. The NDA was submitted in May 2009 and the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 18, 2010. The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems.